

AUA 2008 Best Practice Statement Summary



Primary Treatment

- Patient Selection
 - Organ confined
 - Any grade
 - Negative metastatic evaluation
 - Prior TUR is relative contraindication
- BDFS (5 years)
 - Low risk: 65-92%
 - Moderate risk: 69-89%
 - High risk: 48-91%
- Negative Biopsy
 - 87-98%
- Complications
 - Retention: 1-2 weeks
 - Swelling: 1-2 weeks
 - Numbness: 2-4 months
 - Fistula: 0.05%
 - Incontinence: 1-8%
 - ED (at 12 months): 49-93%
 - Sloughing (2000 data): 0-15%

Salvage Treatment

- Patient Selection
 - Organ confined with positive biopsy confirming disease in prostate
 - PSA < 10 ng/mL (Optimally \leq 4 ng/mL)
 - Long PSA doubling time
 - No evidence of seminal vesicle invasion
 - Life expectancy > 10 years
 - Negative metastatic evaluation
- BDFS (Up to 5 years)
 - 34-86%
- Negative Biopsy
 - 93-94%
- Complications
 - Fistula: 0-3%
 - Incontinence (current studies): <10%
 - ED: >80%
 - Sloughing: 5-10%

Babaian RJ, et al. J Urology 2008; 180(5):1993-2004